Posting of Annual Report and Notice of AGM
TheraCryf plc has announced the posting of its Annual Report and Accounts for the year ended 31 March 2026, along with the Notice of its Annual General Meeting, which will be held on 22 October 2026. The company, focused on developing medicines for addiction and neuropsychiatric disorders, has made its reports available on its investor website. The lead orexin-1 receptor antagonist program is fully funded through pre-clinical trials to clinical readiness, with regulatory submissions for first-in-man studies targeted for 2026.
Select text to share a quote on X · sign in to keep highlights & notes in your TCF notes
TheraCryf plc, the biotech company developing new medicines for addiction and other neuropsychiatric disorders, announces that its Annual Report and Accounts for the year ended 31 March 2026 and Notice of the Annual General Meeting have been posted to shareholders and are now available on the Company website at https://theracryf.com/investors/.
The Company's Annual General Meeting will take place at 2.00 pm on Thursday, 22 October 2026 at Smithfield Offices, 5 St John’s Lane, London, EC1M 4BH.
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.